Ligand id: 4150

Name: cannabidiol

Abbreviated name: CBD

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 0
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 40.46
Molecular weight 314.22
XLogP 6.34
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
CBD is being investigated in various orphan pediatric epilepsy syndromes. The Epidiolex® formulation (a liquid formulation of pure plant-derived CBD) is reported to have met its primary endpoint in Phase III clinical trial (see NCT02091375 and NCT02224703 for current trial details), evaluating the ability of this cannibinoid to reduce convulsive seizures in children with Dravet syndrome, a rare, severe and debilitating form of childhood epilepsy with no currently approved treatment. Epidiolex® has both Orphan Drug Designation and Fast Track Designation from the US FDA for the treatment of Dravet syndrome.
In addition to the Dravet syndrome trials, Epidiolex® is also being evaluated in Lennox-Gastaut syndrome and tuberous sclerosis complex, two other rare and severe pediatric epilepsy disorders.
Click here to link to's list of Phase III Epidiolex® trials.
The manufacturer of Epidiolex®, GW Pharmaceuticals', pipeline page provides details of their other cannabinoid drug candidates and additional conditions being investigated.
Mechanism Of Action and Pharmacodynamic Effects
The analgesic effect of CBD is mediated principally via binding to and activation of CB1 receptors. In addition, CBD has been shown to stimulate vanilloid pain receptors (TRPVs), and to modulate cellular uptake and enzymatic hydrolysis of endogenous anandamide, mechanisms which may contribute towards the drug's pharmacological effects [1].